feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Hansa Medical: Särläkemedelsstatus för anti-GBM
Research Note
2018-07-09
14:24
Hansa meddelade i dag att FDA har beviljat imlifidase (IdeS) särläkemedelsstatus för behandling av anti-GBM.
MS
Mathias Spinnars
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans